Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative Ropivacaine Nerve Block in Hip Fracture
NCT06925789Phase 1Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of ropivacaine in hip fracture, sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Pain Control at 48 hours and Opioid Use at 48 hours. Planned start Jul 2025; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
hip fracture
Beyond the preview
Go deeper on NCT06925789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925789.